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 SCREENING  ASSAY  FOR   SELECTIVE  ESTROGEN   RECEPTOR  
MODULATORS 
Elena Sirbu, BS 
University of Pittsburgh, 2006
Estrogen influences the development and progression of breast cancer and of other types 
of cancer, such as ovarian and lung cancer. The best strategy for prevention and treatment of 
estrogen dependent cancers is to selectively block estrogen activity in the affected estrogen 
dependent tissues. The beneficial role of estrogen in the other tissues should be preserved. One 
of the most common methods to prevent the harmful effects of estrogen is to block the estrogen 
receptor signaling. The intense research in the breast cancer treatment and prevention field 
produced a number of estrogen related compounds. The existing screening assays to test the 
selectivity and potency of these compounds have major limitations. I propose here the 
development and validation of a rapid screening assay for selective estrogen receptor 
modulators. This assay is based on the use of an ERE (estrogen response elements) to drive 
expression of a fluorescent protein that can be visualized directly in living cells. I presented here 
the first step in developing the screening assay, the generation and evaluation of two fluorescent 
clones, ERE-GFP and ERE-DsRed. The clones were introduced in CV-1 cells, together with ER, 
using transient transfection in order to test whether they are under tight estrogenic control. The 
cells were further treated with know ER ligands. These results predict that the clones function as 
expected. A robust signal resulted in the presence of estradiol, while with a pure antiestrogen 
such as ICI 182,780 resulted in very little red/green fluorescence. The vehicle control (ethanol) 
also elicited very little response (fluorescence).  Further, these clones can be stably integrated in 
CV-1 cells together with either ER alpha or ER beta in order to develop a high content screening 
assay for SERMs. The new SERMs identified using this assay can be used eventually in therapy 
of breast or lung cancers or as hormone replacement. In addition, compounds that differentiate 
ERα and ERβ will be valuable tools to further dissect ER signaling pathways. It is important to 
know more about coactivator recruitment, gene expression profile or about the response with ER 
mutations. This will lead to a better understanding of estrogen related cancers and will help 
designing new therapeutic approaches.  
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1.0  BACKGROUND 
1.1 ESTROGEN 
Estrogen is a steroid hormone and it has an essential role in the development and 
maintenance of female secondary sex characteristics. This hormone is produced mainly by the 
ovaries and mediates a broad spectrum of physiologic functions.  
1.1.1 Importance 
Estrogen can have both beneficial and harmful effects. Some of the beneficial effects of 
estrogen are: programs the breast and uterus for sexual reproduction, controls cholesterol 
production protecting the coronary arteries from forming plagues, maintains the proper balance 
between bone buildup and breakdown helping to preserve bone strength. The harmful effects of 
estrogen are mainly a consequence of its ability to promote the cell proliferation in the breast and 
uterus. Breast cancer, endometrial cancer, endometriosis, adenomyosis and leiomyomas are 
diseases that develop and progress in an estrogen-dependent fashion. Also, estrogen status is a 
recognized factor in lung cancer risk in women (1). 
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1.1.2 Estrogen Dependent Diseases 
Breast cancer is the second leading cause of cancer deaths in women today and the most 
common cancer among women. Breast cancer also occurs in men. Although this is much less 
common, breast cancer in men is usually very aggressive. Estrogen influences breast cancer 
development and progression. Also, estrogen seems to be involved in lung carcinogenesis, which 
is the leading cause of death from neoplasia in the United States. Recent studies show that 
estrogens have growth-promoting effects in lung tumors and that estrogen receptor is expressed 
in this tissue (2). Many types of cancer are estrogen dependent. Consequently, the best strategy 
for prevention and treatment is blocking estrogen activity in certain estrogen dependent tissues. 
There is an intensive search for compounds that block estrogen receptor function or inhibit 
estrogen production. Such compounds should inhibit the growth of estrogen responsive cancers 
or even prevent their development. Selective estrogen receptor modulators (SERMs) are a class 
of drugs which have great therapeutic utility in treating ER-positive breast cancers (3). Also, 
SERMs may have therapeutic benefit in non–small cell lung cancer (4).  
1.2 ESTROGEN RECEPTORS 
1.2.1 Estrogen Receptor 
Estrogens act on target tissues by binding to estrogen receptors (ER). ER is a steroid 
receptor and belongs to the family of nuclear hormone receptors. These proteins function as 
transcription factors when they are bound to their ligands.  
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 Classically, estrogen receptor proteins function as transcription factors in the 
nucleus controlling estrogen-regulated genes (5). Besides the nuclear signaling cascade, ER can 
also signal via second messengers, such as receptor-mediated protein kinases, at the membrane 
or in the cytoplasm (6). 
 
1.2.2 Mechanism of Action 
The estrogen receptor has at least two major mechanisms of action. ER can use a 
genomic pathway and a non-genomic pathway.  
Genomic action: 
The genomic ER action occurs in the nucleus, when the receptor binds specific DNA 
sequences directly (classical pathway) or indirectly (non-classical pathway). 
Classical (ERE) pathway: 
In this pathway ER protein functions as a transcription factor in the nucleus. Upon ligand 
binding, estrogen receptor (ER) is activated through phosphorylation and dissociates from the 
heat-shock proteins. Then, the ligand-bound activated ER changes its conformation, dimerizes, 
and binds to specific DNA sequences called estrogen responsive elements (ERE) in order to 
regulate transcription (7, 8) (Fig. 1). In the presence of the natural ligand estradiol, ER induces 
chromatin remodeling and increased transcription of estrogen regulated genes. 
Non-classical pathway:  
AP-1 (9) and SP-1 (10) are alternative regulatory DNA sequences used by both isoforms 
of the receptor, ERα and ERβ, to modulate gene expression. In this case, ER does not interact 
directly with DNA but interacts with other DNA-bound transcription factors such as c-jun or c-
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fos, or with other coactivator proteins (9). Some data suggest that these alternative ER signaling 
pathways, mainly at AP-1 sites, may be involved in Tamoxifen therapy resistance in breast 
cancer (11). 
The same ligand can have different effects on AP-1 (fos/jun)-dependent transcription 
depending on the receptor subtype. For example, E2 is an agonist for ERα but not for ERβ at 
AP-1 elements (12). ERα and ERβ also show differential affinity for p160 coactivators and 
transcriptional responses. As a result of these differences, the overall response of a cell 
expressing ERα or ERβ to a particular ligand cannot be simply predicted.  
Non-genomic pathway: 
There are few mechanisms proposed for the non-genomic ER action or membrane-
initiated steroid signaling. One mechanism involves activation of insulin-like growth factor 
receptor 1, cellular tyrosine kinases, mitogen-activated protein kinases (MAPKs) and 
phosphatidylinositol 3 kinase (13). This action occurs within minutes of the addition of estrogen. 
SERMs such as Tamoxifen may also activate membrane ER (6). Estrogen activates ER in or 
close to the membrane and then ER binds to growth factor signaling elements such as IGFR-1. 
Growth factor signaling is activated and further activates key molecules such as Akt or MAPK 
(14). Estrogen initiates powerful signals for cell survival and proliferation using these pathways. 
Furthermore, ER and its coregulators can be phosphorylated by these kinases. This causes an 
increase in ER nuclear signaling and also in estrogen agonist-like activity of tamoxifen and other 
SERMs (15). 
Another potential mechanism for membrane-initiated ER signaling indirect activation of 
the epidermal growth factor receptor (EGFR) (16). SERMs have differential effects on 
membrane–initiated ER signaling. Tamoxifen, like estrogen, activates membrane ER, while the 
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pure antiestrogen fulvestrant does not activate membrane ER in this way (15). Tamoxifen 
resistance may be explained by this stimulation of ER through non-genomic pathways (15).  
1.2.2.1 ER Signal Transduction using ERE sites: 
 
When ER is activated by agonist ligand binding, conformational changes are induced and 
intracytoplasmic chaperones, such as heat-shock proteins 70 and 90, dissociate from the receptor 
molecule (17). The receptor then interacts with DNA and the transcriptional response is 
modulated by the recruitment of co-regulatory proteins (18). The conformation of the receptor is 
altered by different ligands and by ERE structure. When ER is bound to antiestrogens, a part of 
the receptor (helix 12) is displaced and blocks co-activator access. As seen in crystallographic 
studies, ER alpha reacts to a specific single nucleotide alteration within the ERE by changing its 
DBD conformation by means of a side-chain rearrangement (19). 
The ligand structure and the specific ERE sequence influence ER conformation resulting 
in differential recruitment of co-regulatory proteins to the ER–ERE complex. This can be a 
mechanism for modulation of gene transcription at different EREs. Coregulators recruitment is 
primarily dependent on the ERE sequence when the ERs are bound to 17b-estradiol. By contrast, 
the ERE sequence loses its influence on AF-2-dependent cofactor recruitment when the ERs are 
occupied by anti-estrogens (20).  
The ability of the DNA-bound receptor to modulate transcription is dependent not only 
on cofactors recruitment but also on coactivator/corepressor expression as well as on promoter 
context and ligand structure (3, 21). 
The ERE pathway (Fig. 1) is mainly important in reproductive tissues. Selective estrogen 
receptor modulators bind to the ER causing a conformational change which modifies receptor 
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capacity to dimerize, to form transcription complexes with coactivators and/or to bind to ERE-
dependent genes. Therefore, SERM-bound receptor is unable to activate ERE pathway but the 
new conformation allows ER to activate alternate response domains. These alternate pathways 
are operative in other estrogen responsive tissues, such as bone and vascular tissue. The ligand-
induced conformation of the receptor and the variable availability of some coregulators in 
different tissues make these compounds selective. This might explain why SERMs can be 
agonists as well as antagonists depending on their structure and the cell context. 
 
 
Figure 1 - Model for ER-mediated signal transduction ERE pathway (7).  
 
1.2.2.2 Importance of Coactivators and Corepressors 
 
 
ER coregulators are proteins that are recruited by the receptor to form the transcription 
complexes. The ER needs these factors to mediate cellular responses to endocrine signals.  As 
cellular environments change, ERs can associate with distinct subsets of cofactors depending on 
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binding affinities and availability of these factors as well as on the ligand bound to the receptor. 
The coregulators are generally divisible into coactivators and corepressors. The coactivators turn 
on target gene transcription and the corepressors inhibit gene activation and possibly turn off 
activated target genes. These proteins are part of the transcription complexes and create a bridge 
between ER, chromatin components (histones) and components of the basal transcription 
machinery. Each class of ligand induces a different ER-ligand binding domanin conformation. 
The coregulatory proteins bind to the exposed surface of the receptor, so different ligands induce 
recruitment of different coregulators. 
  The coactivators can be categorized in several subgroups: the p160/SRC 
coactivator family (SRC-1, GRIP-1, AIB-1), CBP/p300 coactivators and SRC-associated 
acetyltransferases, the TRAP/DRIP coactivator complex. The coactivators associate with ER in 
the presence of agonistic ligands. 
The corepressors, like N-CoR (nuclear receptor corepressor) and SMRT (silencing 
mediator of retinoid and thyroid receptors), are recruited to ERs in the presence of antagonistic 
ligands. 
Coregulators influence transcription depending on ER-subtype, the structure of the 
receptor–ligand complex, and the tissue specificity. 
Affinity of the ER alpha interaction with AIB-1 is much higher than that observed for the 
ER beta (22). In contrast to ER alpha, ER beta apparently interacts in a ligand independent 
manner with SRC-1 in vitro. 
Compounds selective for ER alpha or ER beta have different preferences in recruiting 
coactivators (23). The SRC family members have been shown to interact in vivo with both 
isoforms of the receptor (24). In the presence of E2, SRC-1 or GRIP1 are recruited with similar 
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affinity to both ER subtypes. In contrast, both coactivators are more strongly recruited to ER beta 
than to ER alpha in the presence of genistein (25). The capacity of ER ligands to selectively 
modulate the recruitment of coregulators would be useful in the development of pharmaceuticals 
with superior tissue selectivity. 
  Altered expression of ER cofactors has been reported during human breast 
tumorigenesis (26). Hormonally regulated cancers such as breast, uterine, and prostate cancers 
overexpress AIB-1 coactivator (27). Overexpression of AIB-1 is suspected to contribute to 
tamoxifen resistant breast tumors (26). The variation in transcriptional response mediated by ER 
alpha and ER beta might be due to variation in expression levels and differential recruitment of 
coactivators.   
1.2.3 Receptor Domains 
ERs are composed of 6 domains; A to F. Domain A/B (N-terminal domain) encodes a 
ligand-independent activation function (AF1). This region was shown to be a target of the MAP-
kinase regulatory pathway, indicating a cross-talk between signals initiated by growth factors 
and steroid hormones at the level of the receptor (28). The C domain contains a two-zinc finger 
structure which is important in dimerization and DNA binding. The C-terminal domain (E/F 
domain) mediates ligand binding, nuclear translocation and transactivation of target gene 
expression. The ligand binding domain (LBD) also contains a ligand dependent activating 
function (AF-2) and it spans from helix 3 to helix 12. The ligand-binding pocket is composed of 
helixes 3, 4, 5, and 12.The position of helix 12 is altered by ligand binding and influences the 
recruitment of cofactors (29). 
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 1.2.4 Receptor Isoforms 
The biological actions of estrogens are mediated mainly by two receptor isoforms, ER 
alpha (30) and ER beta. The two isoforms are products of distinct genes on different 
chromosomes. Although the two isoforms share mechanistic similarities, they are genetically and 
functionally distinct. ER alpha has biological roles that are different from those of ER beta. 
Knock-out mice deficient in ER beta show a quite distinct phenotype then ER alpha knock-outs. 
The two ER subtypes have different tissue distribution: the ERα subtype is predominant in 
breast, uterus and ovaries, whereas ERβ predominates in lung, bone, endothelial cells (31) and 
prostate (32). These two isoforms have an intranuclear localization. Few membrane-associated 
subtypes of the receptor have been reported lately. An intracellular transmembrane estrogen 
receptor, GPR30, was reported to mediate rapid non-genomic signaling events (33). Also, ER-X 
is expressed in brain and mediates the influences of estrogen on neuronal differentiation, 
survival, and plasticity using MAPK pathway (34).  
 
1.2.4.1 Tissue Distribution 
 
 
The tissue distribution of ER alpha and ER beta transcripts is fairly different, suggesting 
that the two receptor subtypes have distinct functions in different tissues. ER alpha is the 
predominant subtype expressed in the breast, uterus, cervix, and vagina. ER beta is important in 
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other tissues such as the central nervous system, bone, lung, cardiovascular system, ovary, testis, 
kidney and colon. There are synthetic ER ligands that can act in a tissue-specific manner. These 
compounds interact differently with the two isoforms of the receptor and consequently induce 
recruitment of a particular set coregulators as well as binding to different DNA response 
elements. Some tissues express both subtypes of the receptor. When these tissues are exposed to 
a particular ER ligand, the effect of the ligand depends on the ER alpha to ER beta ratio (35). 
1.2.4.2 Genes Regulated by ER alpha and ER beta 
 
Estrogen regulates an important number of genes involved in cell proliferation, apoptosis, 
stimulation of invasion and metastasis, and angiogenesis (13). 
It was demonstrated that most genes regulated by ER alpha are distinct from those 
regulated by ER beta in response to E2 and SERMs. For example, E2 stimulated ER alpha 
regulates genes involved in cell proliferation and signal transduction, while ER beta regulates 
genes that function as tumor suppressors. These results indicate that estrogens and SERMs exert 
tissue-specific effects by regulating unique sets of targets genes through ER alpha as well as 
through ER beta (36).  
In order to develop more tissue-selective and safer drugs for menopausal symptoms and 
estrogen dependent cancers it is important to understand how ER alpha and ER beta regulate 
different genes in response to various ligands. 
 
 
 
 
 10 
 1.2.4.3 Selective Ligands for ER alpha or ER beta 
 
Although the two ER subtypes are both activated by binding 17 -estradiol, the ligand 
binding domains (LBD) have only 56% amino acid identity (37). If the ligand has a 1000- fold 
excess affinity for one receptor over another, this may provide therapeutic selectivity. Agonist 
ligands at ER alpha and ER beta may have selectivity of action based on the perturbation of their 
respective complexes. ER beta has an impaired AF-1 domain compared with ER alpha and the 
necessary synergy with AF-2 is dramatically reduced. These differences suggest that it is 
possible to develop ligands with different affinities, potencies, and agonist vs antagonist behavior 
for the two ER subtypes. In fact there are some known ligands with subtype-selective affinities 
and a degree of subtype selective agonist/antagonist character. In most cases where this 
selectivity is high, it favors ER alpha.  
ER alpha selective ligands: 
Katzenellenbogen and co-workers (38) have synthesized ER subtype-specific ligands: 
triaryl-substituted pyrazoles. The most ER alpha selective ligand, pyrazole, had 120-fold higher 
agonist potency for ER alpha than for ER beta. Another selective ligand, a cis-diethyl-substituted 
tetrahydrochrysene and shows full ER alpha agonism but pure ER beta antagonism (39). This 
compound differs from antiestrogenic compounds such as Tamoxifen and Raloxifene, which are 
full antagonists on ER beta but have negligible agonist activity on ER alpha. 
Tetrasubstituted propylpyrazole (PPT) has a 410-fold binding selectivity for ER alpha 
and is an ER alpha-specific agonist, as it activates gene transcription only through ER alpha (40). 
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HPTE (2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane ) behaves as an ER alpha agonist 
and an ER beta antagonist (41) in human hepatoma cells (HepG2) and HeLa cells. 
ER beta selective ligands: 
Ligands that are ERß selective are also known. Some phytoestrogens such as genistein 
and coumestrol activate both ER isoforms but they preferentially bind ER beta (32). DPN (2,3-
bis(4-hydroxyphenyl) propionitrile) acts as an agonist on both ER subtypes, but has a 70-fold 
higher relative binding affinity and 170-fold higher relative potency in transcription assays with 
ER beta than with ER alpha (42). 
1.3 DRUGS THAT TARGET THE ESTROGEN RECEPTOR 
There are two sources of estrogen in estrogen-dependent diseases. One is secretion by the 
ovaries and the other one is biosynthesis in local tissue catalyzed by enzymes such as aromatase. 
This enzyme catalyzes the conversion of testosterone to estradiol. Aromatase is located in 
estrogen-producing cells in the adrenal glands, ovaries, placenta, testicles, adipose tissue, and 
brain. A strategy to block estrogen signaling involves systemic inhibition of estrogen 
biosynthesis through the use of aromatase inhibitors. These compounds have limitations also, the 
most important being the long-term impact of estrogen deprivation (osteoporosis, 
hypersensitivity to low levels of estrogen) (43). 
Another strategy to treat estrogen-dependent cancers is to block the activity of the 
estrogen receptor using specific ligands. Endocrine therapy uses selective estrogen receptor 
modulators (SERMs), such as Tamoxifen, for treatment and prevention of breast cancer (44). 
Although Tamoxifen is widely used and highly effective, a considerable percent of the patients 
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fail to respond to treatment or acquire resistance in time. Tamoxifen has adverse side effects, 
mainly due to its partial agonist action in endometrium.  
Besides Tamoxifen, second, third and fourth generations of SERMs are now available 
(Fig. 2). Second-generation SERM, Raloxifene is an antiestrogen in breast, but unlike tamoxifen, 
it has significantly reduced uterotropic activity and prevents hip fractures (45). Yet Raloxifen has 
several undesirable effects, including hot flushes and venous thrombosis (46). The risk benefit 
ratio has yet to be clinically determined for a third generation of SERMs (lasofoxifene and 
basofoxifene). Arzoxifene (third generation SERM) and Acolbifene (fourth generation SERM) 
are both more potent than Tamoxifen and they are active in metastatic breast cancer (47). 
Acolbifene, but not Arzoxifene, inhibited growth of Tamoxifen resistant breast cancer cell lines. 
Nevertheless, these drugs induce hot flashes, fatigue and muscle or bone pain.  
 
 
 
Figure 2  – Representative chemical structures of the fourth classes of selective estrogen receptor 
modulators (SERMs)(3) 
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 Although the current classes of drugs have had a positive impact on the morbidity and 
mortality associated with breast cancer, they have important disadvantages. Considering that 
SERMs are to be used in healthy women for breast cancer prevention or to treat menopausal 
symptoms, it is crucial to develop more favorable drugs.  
More selective drugs will potentially have improved therapeutic utility. Since the two 
isoforms of the ER have different tissue distribution, ER antagonists that selectively inhibit only 
one isoform of the receptor would have fewer side effects. An ideal SERM would block the 
estrogen effects in reproductive tissues while retaining the positive estrogenic character in non-
reproductive tissues such as bone, liver, and the cardiovascular system.  
The benefits of finding selective compounds are numerous. One would be finding drugs 
that target only a specific pathway involved in disease progression. The ability of the DNA-
bound receptor to modulate transcription is dependent on coactivator/corepressor expression. 
The nuclear receptor coactivator amplified in breast cancer 1 (AIB1) is overexpressed in breast 
cancer (27). Since ER alpha is the predominant isoform of the receptor in breast tissue, a 
compound that will specifically inhibit ER alpha – AIB1 modulated transcription may be used to 
selectively target this pathway in breast cancer while leaving the other ER pathways operative. 
Another possibility would be to combine two selective drugs. It was shown that when ERβ is 
coexpressed with ERα in breast cancer, the tumor sensitivity to 4-hydroxytamoxifen is increased 
and the overall prognostic of the disease is better than in patients with low or no expression of 
ERβ (48). Also, the two isoforms of the receptor play different roles in mammary epithelial cells. 
ERα induces proliferation while ERβ has a role in apoptosis (49). So, a combination of two 
compounds (a selective ERα antagonist and a selective ERβ agonist) will be more potent in 
breast cancer treatment. 
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2.0  NEW SCREENING ASSAY 
2.1 RATIONALE FOR THE PROJECT 
The intense research in the breast cancer treatment and prevention field produced a 
number of estrogen related compounds that have shown great therapeutic promise. There has 
been much effort put into the design and synthesis of libraries of compounds that target the 
estrogen receptor (50, 51). The goal is to find compounds that block the effects of estrogen in 
some tissues and conserve the positive estrogenic character in others.  So far, there is no rapid 
screening assay to test these compounds. The screening assays used to date to test compounds 
that bind ER have serious limitations.  
I propose here the development and validation of a rapid screening assay to follow ER 
function in vivo. This assay is based on use of ERE (estrogen response elements) to drive 
fluorescence that can be visualized directly in living cells. Additionally, no exogenous substance 
is necessary to detect fluorescence, so the determinations will have less variability. Reporter 
gene and traditional biological assays require cell lysis to measure transcription. A benefit of this 
system is that the cells do not have to be lysed to measure fluorescence, so they can be studied 
easily at different time points. Using this system, I will be able to very quickly screen a large 
number of compounds under the same conditions and with a functional readout. The screening 
can be done simultaneously for ER alpha and for ER beta.  
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 2.2 MATERIALS AND METHODS 
Materials: 
17 -Estradiol (E2) was purchased from Sigma-Aldrich (St. Louis, MO). They were 
prepared as 1 x 10-2 M stocks in 100% ethanol and stored at -20°C.  
CMV-ER  contains the full-length coding sequence of human ER  (595 amino acids). 
ERE-tk-luciferase contains a single ERE cloned upstream of the thymidine kinase promoter and 
the luciferase gene (gift of Don DeFranco, Dept. of Pharmacology, University of Pittsburgh).  
The pcDNA5/FRT encoding the Hygromycin resistant gene was purchased from 
Invitrogen. 
The pEGFP-N1 and pDsRed2-N1 plasmids are commercially available (Clontech). 
 DMEM (Dulbecco's modified Eagle's medium with 4.5 g/L-glucose) was purchased from 
Mediatech, Herndon, VA and supplemented with 10% fetal bovine serum (HyClone 
Laboratories, Inc., Logan, UT) and 100 units/ml penicillin-streptomycin (Invitrogen, Carlsbad, 
CA). 
Construction of ERE-GFP reporter gene: 
The Luciferase reporter gene was excised from the plasmid ERE-tk-Luc by restriction 
digest with the enzymes StyI and XhoI. An AflII-XhoI fragment containing the coding region of 
EGFP gene was excised from pEGFP-N1 (Clontech) and ligated into digested ERE plasmid to 
generate ERE-GFP. A 1500 bp PvuII-AseI fragment was containing ERE-GFP clone was then 
inserted into the pcDNA5/FRT (Invitrogen) at the multiple cloning site. This makes the ERE-
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GFP clone suitable for stable transfections, since pcDNA5/FRT contains a Hygromicin resistant 
gene. The resulting ERE-GFP plasmid contains a copy of ERE sequence a TATA box and a tk 
promoter upstream from the GFP gene. 
Construction of ERE-DsRed reporter gene: 
The Luciferase reporter gene was excised from the plasmid ERE-tk-Luc by restriction 
digest with the enzymes StyI and XhoI. An AflII-XhoI fragment containing the coding region of 
DsRed gene was excised from pDsRed2 (Clontech) and ligated into digested ERE plasmid to 
generate ERE-DsRed. The resulting ERE-DsRed plasmid contains a copy of ERE sequence a 
TATA box and a tk promoter upstream from the DsRed gene. 
Construction of ER alpha/Neomycin gene: 
An EcoRI-EcoRV fragment containing the coding region of ER alpha gene was excised 
from CMV-ERalpha plasmid and ligated into pcDNA3.1 plasmid to generate ER 
alpha/Neomycin plasmid. This makes the plasmid suitable for stable transfections, since 
pcDNA3.1 contains a Neomycin resistant gene. 
Cell culture and transfections: 
CV-1 cells (African green monkey kidney cells) were cultured in Dulbecco's modified 
Eagle's medium with 4.5 g/L-glucose (Mediatech, Herndon, VA) supplemented with 10% fetal 
bovine serum (HyClone Laboratories, Inc., Logan, UT) and 100 units/ml penicillin-streptomycin 
(Invitrogen, Carlsbad, CA) at 37°C in a humidified 5% CO2 atmosphere. All cultures were in a 
passaged every 3-4 days. For transient transfection assays, cells were plated in 10mm dishes at a 
density of 1X106 cells per well in phenol red-free Dulbecco's modified Eagle's medium 
(HyClone) containing 10% charcoal-dextran-stripped fetal bovine serum (HyClone). CV-1 cells 
were transfected using Lipofectamine reagent (Invitrogen, Carlsbad, CA) according to the 
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manufacturer's protocol. Transfections contained 2 µg of reporter plasmid and 2 µg of ER  
expression vector. The transfection complexes were incubated with cells for 5 h and then DMEM 
media added to achieve a final concentration of 10% CSS.  After 16 h, the medium was replaced, 
and the cells were treated with vehicle or ligand for an additional 24 h. (CSS). Transfection 
efficiency has been estimated to be 10-20%. The amount of DNA per sample was kept constant 
in all experiments. The transfection complexes were incubated with cells for 5 h and then 
DMEM media added to achieve a final concentration of 10% CSS.  
Generate ER alpha/Neomycin stable cell line: 
For stable transfections, 70% confluent CV-I cells were transfected by Lipofectamine 
following the protocol provided by the supplier (Life Technologies, Rockville, MD). For 
transfection, 5 × 106 cells were suspended in 3 ml of Opti-MEM I (Life Technologies) containing 
40 g of ER alpha/Neomycin plasmid in a 100 mm tissue culture dish. After transfection, cells 
were plated in complete medium (DMEM supplemented with 10% FBS) for 48 hr, and then 
selected in media containing 400 µ/ml G418. Several individual clones were isolated and 
expanded. 
2.3 RESULTS 
2.3.1 Principle of the Screening Assay 
The new screening assay will follow the ER-mediated transcription in living cells. An 
ERE promoter element in front of a fluorescent protein reporter gene will be used to evaluate 
estrogenic transcriptional activity, driven by test compounds. The consensus ERE 
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(AGGTCAnnnTGACCT) in front of the tk promoter will control the expression of the 
fluorescent protein. The amount fluorescence visible in living cells should be proportional to the 
amount of transcription through ER bound to the ERE enhancer element. 
 
2.3.2 The Screening Assay Development 
 
In order to develop a new assay, I constructed reporter plasmids that have an ERE 
element, upstream of thymidine kinase (tk) promoter controlling a GFP or a DsRed reporter 
gene. Stable CV-1 transfectants can be developed in which a single copy of the ERE-DsRed 
reporter and ER alpha is integrated. To allow identification of subtype selection, I also 
constructed a second reporter plasmid that has an ERE element upstream of thymidine kinase 
(tk) promoter controlling a GFP (green fluorescent protein) reporter gene. This reporter system 
and ER beta can be stably integrated in CV-1 cells (CV-1B). In this case, any compound that 
binds ERβ and folds it for coactivator interaction will activate the transcription from the ERE 
enhancer, making GFP and green cells.  The key experiments can combine all four of these 
elements as stably integrated DNA: the ERE-driven GFP reporter, the ERE-driven DsRed2 
reporter, the wild-type ERα that binds EREs in CV-1A and the wild-type ERβ that binds ERE 
elements in CV-1B cells.  ERα and ERβ activity will therefore be assayed simultaneous in living 
cells using the two cell lines: CV-1A and CV-1B. 
A summary of expected results is presented in Table 1. 
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Table 1- Screening assay for selective ER compounds - Expected results 
Cells /Treatment 
CV-1B cells 
(CV-1 cells + ERE-GFP+ERβ)
CV-1A cells 
(CV-1 cells + ERE-RFP+ERα) 
Estradiol Green Red 
4 OH-Tamoxifen Some green Some red 
ICI 182,780 No green No red 
Ethanol (control) No green No red 
Selective ERα antagonist No green Some Red 
Selective ERβ antagonist Some Green No red 
 
 
2.3.3 Characterization and Optimization of the Assay 
Transient transfections in CV-1 cells in the presence of known ER ligands were used to 
test ERE-DsRed and ERE-GFP plasmids. The best results were attained using ERE-GFP in 
combination with ER beta and ERE-DsRed in combination with ER alpha. This is probably due 
to the fact that ER alpha is more potent than ER beta. In addition, GFP is brighter than DsRed in 
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the same conditions. As expected, the amount of red/green fluorescence, visible in living cells, 
was dependent on known ligand capacity to modulate transcription (Fig. 3 and 4). A robust 
signal resulted in the presence of estradiol, while with a pure antiestrogen such as ICI 182,780 
(52) resulted in very little red/green fluorescence. The vehicle control (ethanol) also elicited very 
little response (fluorescence).  
A CMV-ERα plasmid has been stably integrated in CV-1 cells using G418 as a selectable 
marker. Western blots will be used to confirm that ER alpha is indeed express by these cells. To 
test ER alpha activity in these cells, the G418 resistant colonies will be transiently transfected 
with ERE-tk-LUC plasmid and treated with different ligands.  
 
 
 
 
Figure 3 - The ERE-DsRed plasmid is under tight estrogenic control. 
CV1 cells were co-transfected with CMV-ERα (2μg) and ERE-tk-DsRed (2μg). After 24h, E2 (a) (agonist), 
ICI 182 (b) (antagonist) or the vehicle control ethanol (c) were added. The final concentrations of each compound 
were (1×10-7M). The pictures are taken after additional 48h. The exposure time is the same for all pictures (700ms). 
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 Figure 4  - The ERE-GFP plasmid is under tight estrogenic control 
CV1 cells were co-transfected with CMV-ERβ (2μg) and ERE-tk-GFP (2μg). After 24h, E2 (a) (agonist), 
ICI 182 (b) (antagonist) or the vehicle control ethanol (c) were added. The final concentrations of each compound 
were (1×10-7M). The pictures are taken after additional 48h. The exposure time is the same for all pictures (500ms). 
 
ERE-tk-DsRed reporter plasmid will also be stably integrated in the same cells (CV-1A). 
Another cell line (CV-1B) should have CMV-ERβ plasmid and ERE-GFP reporter stably 
integrated. The exact level of transcription induced by compounds that look more promising can 
be quantified using Luciferase reporter gene construct, such as ERE-tk-Luc. 
 Once the whole system is set up and validated with known compounds, it can be 
used to determine the estrogenic character of new SERMs. Some of the compounds that can be 
tested are DTACs (1,1-dichloro-2,2,3-triarylcycloprpanes) (Fig. 5), which have antiestrogenic 
character. They block uterine growth in mice and also block growth of MCF-7 estrogen-
dependent breast cancer cells (51).  
Our group previously demonstrated that the novel class of compounds 1,1-dichloro-2,2,3-
triarylcyclopropanes (DTACs) function as anti-estrogens and block ERα-mediated transcription 
from an ERE-driven reporter construct and estrogen-mediated stimulation of endogenous target 
genes c-myc and cyclin D1 in breast cancer cells. CV-1 cells were cotransfected with CMV-ER , 
CMV- -galactosidase, and ERE-tk-luciferase and treated with different ligands. 
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Figure 5 – DTAC chemical structures. 
First line of this panel shows well characterized ER ligands, such as estradiol (the natural ligand of ER), 
diethystilbestrol (synthetic agonist), 4-hydroxytamoxifen (the active metabolite of Tamoxifen – a partial agonist) and 
ICI 182,780, a pure antiestrogen. Second and third lines present various DTACs chemical structures starting with 
the parent compound, Analog II(53). 
 
Results presented in Fig. 6a show that DTACs do not stimulate ER alpha transcription 
from an ERE site. To show that these compounds are not general transcription inhibitors, their 
ability to modulate transcription from an AP-1 DNA binding element was analyzed (Fig. 6b). 
TPA (12-O-tetradecanoylphorbol-13-acetate) was used to activate signal transduction in CV-1 
cells (ER alpha negative) transfected with AP-1 –Luciferase plasmid. DTAC compounds, as well 
as other estrogenic or antiestrogenic compounds, had no effect on TPA stimulated transcription. 
This suggests that DTACs are not general transcription inhibitors (53). 
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  a     b 
 
Figure 6 - DTACs inhibit ER alpha mediated transcription but they are not general transcription 
inhibitors(53). 
 (a)CV-1 cells were cotransfected with CMV-ER , CMV- -galactosidase, and ERE-tk-Luciferase and 
treated with known compounds (1 x 10-8 M) or with DTACs (1 x 10-5 M).  
(b) CV-1 cells were transfected with AP-1-tk-luciferase. The following day, cells were treated as indicated. 
The activity of Luciferase was measured for both experiments after 24 hours of treatment. 
 
Because of the potential differences in ERα and ERβ activity, a series of studies was 
conducted to evaluate the behavior of DTAC compounds in the presence of ERβ. The ability of 
DTACs to modulate ERβ-mediated transcription from estrogen response elements (EREs) (Fig. 
7) was evaluated.  
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 Figure 7 - The ability of DTACs to modulate ER-mediated transcription from estrogen response elements 
(EREs)(53) 
CV1 cells were co-transfected with CMV-ERα or CMV-ER β, CMV-β-galactosidase, and ERE-tk-
luciferase. After 16h, E2, DES, ZOHT or the DTAC compounds were added. The final concentrations of each 
compound were: E2, DES, ZOHT, ICI (1×10-8M), Analog II and DTACs (1×10-5M). After an additional 24h, the 
cells were harvested and luciferase and β-galactosidase activity measured. To control for transfection efficiency, 
luciferase activity was normalized to β-galactosidase activity. Data are expressed relative to the activity of E2, 
which was set at 100%. Bars represent the mean ± SD of at least 3 independent experiments.  
 
In the presence of ERβ at EREs, BDRM72, BDRM23, and BDRM83 displayed agonist 
activity that was equal to or greater than that observed for the well-characterized partial agonist, 
ZOHT (Fig. 7). These results contrast with those obtained with ERα, wherein BDRM81 and 
BDRM72 but not BDRM23 or BDRM83 displayed agonist activity. Taken together, these data 
indicate that the structural determinants of DTAC stimulation of ER-mediated transcription are 
different for ERα and ERβ (53) . 
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Additional controls can be added in order to measure the background fluorescence. For 
this purpose we can use plasmids similar with ERE-GFP and ERE-DsRed but lacking the ERE 
site. Other controls should include experiments in the presence of SERMs solvents, such as 
DMSO. Also background fluorescence should be determined by measuring fluorescence in the 
absence of any ligand. 
In order to optimize the assay, a time course experiment can be used to find out when in 
time the difference between agonists and antagonists is reflected best in the amount of 
fluorescence visible. The ligand bound receptor takes minutes to bind to DNA and activate gene 
transcription (54). Fluorescence develops within 24 hours of transfection using pEGFP-N1 or 
pDsRed2-N1 and increases in intensity in the next 2-3 days. The CV-1A and CV-1B cells will 
be treated with estradiol or with ICI 182,780 and the fluorescence will be measured every 12 
hours. The last time point will be after 120 hours when the original florescent plasmids were 
show to have maximum fluorescence intensity (Clontech). 
Another optimization for a more uniform fluorescent signal would be to synchronize the 
cells growth. A regular batch of cultured cell grows randomly and each individual cell is 
asynchronous with the others. For the purpose of this assay it would be more useful to have the 
cells going through the cell cycle synchronously, and consequently synthesizing the fluorescent 
protein in the same time. Synchrony can be induced by hot-cold or light-dark intervals. 
2.3.4 Potential Pitfalls and Alternative Approaches 
The sequential stable integration of two different plasmids (ER and ERE-fluorescent 
protein) in the same cells might be a difficult task. Alternatively we could construct a single 
plasmid that would contain both genes (ER and ERE- fluorescent protein). In this case we will 
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have to stably integrate only one plasmid (ER alpha/ERE-DsRed) in CV-1 cells to generate CV-
1A cells and ER beta/ERE-GFP plasmid to generate CV-1B. One concern is that such a plasmid 
is very large (approximately 10kb). That size would be very difficult to transfect. Another 
concern is that ER expression is driven by a CMV promoter, which is a very strong promoter. 
That can impair expression of DsRed, respectively GFP (driven by ERE-tk promoter which is 
weaker) if they are both in the same plasmid. 
 In case the amount of fluorescent protein expression is not enough to generate a 
detectable fluorescent signal, multiple estrogen-responsive elements can be used to generate 
(ERE)n – GFP/DsRed clones. Multiple EREs upstream of the promoter will yield a stronger 
signal that a single ERE copy (55). Also, fluorescent clones that have a nuclear localization 
signal (NSL) tag might be useful. NLS-tagged ERE-GFP/DsRed clones would generate a 
stronger nuclear signal and less, if any, cytoplasmic background fluorescence. 
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3.0  DISCUSSION 
Selective estrogen receptor modulators (SERMs) show great promise in treatment of 
cancer, osteoporosis and endocrine disorders. Tamoxifen, one of the first characterized SERMs, 
has been successfully used in breast cancer therapy (56, 57). Although many patients benefit 
from currently available SERMs, these drugs have major limitations. There is a substantial effort 
put into developing new, more efficient SERMs (50, 51). Many new compounds derived from 
this intensive search and they need to be analyzed fast but also in a comprehensive manner.  
I proposed here a new screening assay that can be used to sort through SERMs. The 
newly synthesized compounds can be screened for estrogenic/antiestrogenic activity at the level 
of gene transcription. The principle of the screening assay is the following: an ERE promoter is 
cloned in front of a fluorescent protein gene and controls the protein expression. So, the 
fluorescent visible in cells should be proportional to the ER ligand capacity to modulate 
transcription through ERE. This is a noninvasive assay, unlike the conventional reporter gene 
assays, that can be used to study the classical estrogen receptor-mediated gene activation. This 
technique has various applications. Besides compound screening, the assay can be further 
expanded to analyze promoters and cofactors importance, and to analyze the biological function 
of estrogen receptor mutants. I have been able to construct an important part of the materials 
needed for the assay. The results presented here predict that the assay proposed is going to work 
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as anticipated: the fluorescence visible in living cells is proportional to the ability of the ligands 
to modulate ER transcription through ERE. 
A number of in vitro and in vivo assay were used so far in order to characterize 
compounds designed to be estrogen receptor ligands. The ligand binding assay measures only the 
extent of the binding affinity between ligand and receptor. This kind of assay is an in vitro assay 
and offers limited information about the ligand character. There is no information about the 
agonist/antagonist activity, the effect on gene transcription or about the toxic effects on a living 
cell. Other assays, such as the cell proliferation assays  or rodent uterotrophic assays (58), are 
performed in vivo but they lack specificity (ER alpha versus ER beta specific ligands) and do not 
provide any direct information on transcription. The reporter gene assays, such as the Luciferase 
assays, require time and they have a lot of variability. Other assay use truncated forms of the 
receptor. For example the LBD-flanked by the FRET  donor fluorophore and the acceptor 
fluorophore is used to predict the agonist/antagonist character of the ligands, but not the full 
length of the receptor (59).  
The new assay proposed here provides many advantages over conventional reporter 
genes for the study of transcription factor action. It is an in vivo assay that can screen fast a big 
number of compounds in the same conditions and with a functional readout. Using this assay we 
can specifically test the effect of the ligands on the ERE-mediated transcription, it will not test 
just the ligand-receptor interaction or the proliferation of the cell in the presence of various 
ligands. This assay offers information about ligand selectivity for ER alpha or ER beta. In 
addition, fluorescent reporters can measure gene expression of a single living cell in real-time.  
I presented here the assembly of two clones, ERE-GFP and ERE-DsRed. In order to test 
the functionality of these clones I performed transient transfections in CV-1 cells. These cells are 
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one of the most suitable ones for the purpose of this screening assay. They exhibit no 
endogenous estrogen receptors or any growth responses to estrogens or antiestrogens. Therefore 
it is possible to generate cell lines that contain only one isoform of the receptor. Additionally, 
stable cell lines should have similar levels of ER expression in all cells. CV-1 cells grow well in 
charcoal stripped serum, unlike other type of cells frequently used to study ER ligands (such as 
MCF-7 cells). These cells have been used for a number of studies of steroid receptors and they 
respond accurately with exogenously added receptors and receptor constructs. Also, CV-1 cells 
are easy to transfect, available, inexpensive and suitable for stable transfections. 
The clones were introduced in CV-1 cells, together with ER, using transient transfection 
in order to test whether they are under tight estrogenic control. The cells were further treated 
with know ER ligands. The results (Fig. 2 and Fig. 3) show that in the presence of full agonist 
estradiol ER mediated transcription is stimulated through ERE pathway. The amount of 
fluorescence visible in the cells treated with full antagonist ICI 182 is very low, similar to the 
one obtained with the vehicle control ethanol. ERE-GFP and ERE-DsRed clones function under 
tight estrogenic control in the presence of estrogen receptor. These results predict that the clones 
function as expected and they can be used to develop the SERM screening assay.  
One limitation of this assay system is that it investigated only the transcription through 
ER bound to the ERE enhancer element. ERs have also been shown to modulate gene expression 
at alternative regulatory DNA sequences such as AP-1 (9), SP-1 (10). Alternative ER signaling 
through AP-1 sites is of great interest since it was suggested that it is involved in the onset of 
Tamoxifen therapy resistance in breast cancer (11). An assay that would have stable cell lines 
that express ER alpha and AP-1-DsRed, respectively ER beta and AP-1-GFP would give 
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information about this alternative ER signaling pathway. Also, this assay does not address the 
non-genomic effects of the estrogen receptor (60).  
There are other limitations of this assay. One of them derives from the fact that stably 
transfected cells are going to be used. Transfection results in an overexpression of the gene of 
interest. Consequently, the transfected cells might have modified phenotype and modified gene 
function compared to the real gene. Other limitations of the screening assay are limitations 
common to all cell-based assays. One would be that it takes a long time to develop and optimize 
the assay. The standardization of the cell culture conditions, the stability of the recorded signal 
and the sensitivity of detection are other challenges of the cell-based assays. This type of assays 
has some variability so a big number of cells need to be analyzed to get convincing results. Also, 
these assays generate a considerable amount of data that needs to be analyzed. The statistical 
methods used to interpret the data are not trivial and have limitations.  
No matter how complex is a cell based assay it can not predict all the effects of a drug on 
an organism.  
I presented here the first step in developing the screening assay, generating and 
evaluating the fluorescent clones. Further, these clones can be stably integrated in CV-1 cells 
together with the estrogen receptor. Stable CV-1 transfectants can be developed so that they have 
a single copy of the ERE-DsRed reporter and ER alpha is integrated (CV-1A). The ERE- GFP 
reporter system and ER beta can be stably integrated in CV-1 cells (CV-1B) to allow 
identification of ER subtype selection. ERα and ERβ activity will therefore be assayed 
simultaneous in living cells using the two cell lines: CV-1A and CV-1B. CV-1A cells will be 
treated with known ER ligands in order to validate this reporter system. The amount of red 
fluorescence visible in living cells should be dependent on known ligand capacity to modulate 
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ER alpha regulated transcription. After the initial screening using DsRed (red fluorescent 
protein) as a reporter gene, the transcription can be accurately quantified using an ERE-tk-Luc. 
CV-1B cells will be also tested using know compounds as described above. These assays can be 
performed on a Cellomics ArrayScan multiparameter fluorescence imaging instrument for high-
content screening (HCS).    
The high content screening generates a huge amount of data in the form of photographic 
images of cells. The images captured from each well will allow comparison between 
fluorescence yielded by unknown compounds and known standards. These experiments have 
variables (plating density, cell number per field, number of fields scanned per well) that can 
modify fluorescence independent of ligand action. A statistic test, such as Kolmogorov-Smirnoff 
(KMG) statistic described by Smellie A. and col.(61), will be used measures the difference 
between fluorescence distributions. The corrected Kolmogorov score (S) will be used for 
pairwise comparison. 
 
 
A value of 0 for this score means the distributions of the values are identical and a value 
of 1 means that the distributions are nonoverlapping and distinct. This will compare the 
distribution of values derived from the images for a row of wells (W) with those of another row 
of wells (D). In the presented formula S (W,D, P)  is the corrected Kolmogorov of the Wth test 
well, when compared against the set of negative controls wells D using parameter P, W is the 
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well being compared, KMGp (W,Di) is the Kolomogorov-Smirnoff statistic computed using the 
distribution of parameter P values in the well test W and the ith negative control well Di, P is the 
parameter used for computation (in this case average fluorescence inside the nucleus if we 
consider that there are 4 images generated for each well), Di is the ith negative control well on 
the plate, ND is the number of control wells per plate, and BC is the background KMG value 
defined as the mean KMG distance between all pairs of negative control wells. The background 
for these experiments will be the fluorescence yielded by the cells without any treatment. This 
corrected score measures the average KMG distance between a test compound and all negative 
control wells on the plate, with a correction for the background distance between control wells. 
The cutoff for the corrected Kolmogorov score is typically between 0.02 and 0.1. S values in this 
interval indicate that the experiment is reproducible and that the fluorescence varies because of 
the ligand not because of the way the experiment is setup. 
Further we can compare the values of the fluorescence generated by a test compound 
with the one generated by a control compound. The goal of the screening is to identify 
compounds that specifically inhibit transcription / fluorescence. To find compounds that inhibit 
fluorescence similar to compound ICI 182,780 we will calculate confidence interval (95%) 
around the mean fluorescence of ICI 182,780 using the following formula: 
 Mean + 1.96xSD/ sqrt (n)  
We consider “hits” the compounds that provide a mean fluorescence within the confidence 
interval. 
The new SERMs identified using this assay can be used eventually in therapy of breast or 
lung cancers or as hormone replacement. In addition, compounds that differentiate ERα and ERβ 
will be valuable tools to further dissect ER signaling pathways. It is important to know more 
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about coactivator recruitment, gene expression profile or about the response with ER mutations. 
This will lead to a better understanding of estrogen related cancers and will help designing new 
therapeutic approaches.  
The steroid receptors are a large class of ligand activated transcription factors. Steroids 
imbalance or disruption of the pathways involved in hormone action lead to diseases like breast 
and ovarian cancer, prostate cancer and osteoporosis. The steroid receptors role in many aspects 
of cell growth and metabolism makes them important targets in drug discovery. A fast and 
accurate screening assay can optimize the drug discovery process. Many compounds can be 
screened in the same time reducing the time required to develop new, more selective drugs. The 
assay proposed here satisfies not only these requirements but, with few modifications, can be 
used to understand better the estrogen receptor mechanism of action. Once developed and 
validated this assay can be expanded to study other steroid receptors (such as progesterone 
receptor, androgen receptor, mineralocorticoid receptor or glucocorticoid receptor) and to screen 
their ligands. Besides drug screening and mechanistic studies, this assay can be used to test 
manmade or environmental chemicals found in soil, water and food for their potential effect as 
endocrine disruptors.  
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